Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
BTIG Reiterates Buy Rating on Acumen Pharmaceuticals, Inc. (ABOS)
August 14, 2024 6:12 AM EDTBTIG analyst Thomas Schrader reiterated a Buy rating and $11.00 price target on Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS).
The analyst comments "Enrolling a trial with a placebo arm when an active commercial drug is available is historically challenging, so we see Acumen's comments about the rapid enrollment of the P2 trial for Sabirnetug as very encouraging. Talking with management, both the therapeutic premise of a safer antibody that may also be more... More
